Eli Lilly’s weight loss drug Zepbound has shown better results than rival Novo Nordisk’s Wegovy, with patients taking Zepbound losing an average of 20% of their weight compared to 14% for Wegovy. The study monitored 751 people and found that more patients on Zepbound achieved at least a 25% weight loss. This news is expected to fuel market-share gains for Zepbound, which brought in $1.3 billion in sales in the third quarter of this year. Shares of Eli Lilly rose nearly 2.4%, or about $19, to $833.21 on Wednesday, marking an all-time high.
Source: https://finance.yahoo.com/news/zepbound-tops-wegovy-weight-loss-152107844.html